Paraquat's 700 Holdouts: Why a Federal Judge Wants to Speak to Every Opt-Out Plaintiff Before the Settlement Fails

A federal judge overseeing the paraquat litigation has ordered a lawyer to bring each of his roughly 700 clients who rejected the global settlement before her to hear from them directly. The October 2026 orders are the court's bluntest move yet to find out whether the settlement is failing on its merits — or on its paperwork.

  • 6,602 actions were pending in MDL 3004 as of the Judicial Panel's October 1, 2026 report, out of 8,495 filed since consolidation.
  • Only 49 of attorney R. Allen Smith's 750 clients were participating in the proposed settlement, the judge said on October 14, 2026 — about 700 had opted out.
  • The parties announced a settlement framework in April 2025, and the court identifies September 3, 2025 as the date the master settlement agreement was signed — yet its terms remain confidential and no public payment schedule exists.
  • The first bellwether cases never reached a jury: they were dismissed in April 2024 after the court excluded the plaintiffs' general causation expert.
  • Syngenta ended global production of paraquat at the end of June 2026, while maintaining that the herbicide is safe and that it will keep fighting cases that do not settle.

For plain-language explainers on related legal topics, the Problem Solved channel publishes guides that help readers understand their options before they act.

What the judge ordered in October 2026

A multidistrict litigation, or MDL, gathers similar federal cases before one judge for pretrial work. Here that judge is Chief Judge Nancy J. Rosenstengel of the Southern District of Illinois, and the litigation is In re Paraquat Products Liability Litigation, MDL No. 3004, in which farmers, applicators, and others allege that exposure to the herbicide paraquat caused Parkinson's disease.

On October 14, 2026, Judge Rosenstengel ordered R. Allen Smith of The Smith Law Firm to disclose any outside funding behind his cases and to attend fortnightly court conferences so she can speak to each of his clients who opted out. Within 14 days, Smith was also ordered to produce his opt-out clients' plaintiff fact sheets and set their depositions. Her stated concern: that the decisions to reject the settlement were made by the plaintiffs themselves, fully informed.

Why so many plaintiffs walked away

A September 2026 press report put the total number of plaintiffs who had rejected the proposed deal above 900, with some firms reporting rejection rates of 80 to 100 percent among their clients. A global deal only works if enough plaintiffs accept it, so a rejection rate on that scale leaves the agreement far short of the buy-in it needs to hold.

The court has also questioned the quality of the claims on both sides. At an August 27, 2026 hearing, the judge pointed to cases with missing fact sheets, uncertain product exposure, and questions over whether some claimants actually had Parkinson's disease — and cited testimony suggesting at least one plaintiff had never been told about the settlement at all. That record is why she now insists on hearing from the plaintiffs herself — while saying plainly that she cannot force anyone to settle.

The June order that raised the bar for holdouts

On June 22, 2026, Judge Rosenstengel entered a detailed order governing plaintiffs who rejected the settlement, were found ineligible, or filed after the settlement program was created. Each must now produce a plaintiff fact sheet, medical records and a summary of them, evidence of paraquat use, witness affidavits, and an explanation of which state's law applies.

Plaintiffs who rejected an offer must also meet personally with Special Master Randi Ellis to confirm they understand the offer and the risks of litigating — and a plaintiff who still opts out must sign a written certification confirming the decision was informed. The court has also used a Lone Pine order, a device requiring plaintiffs to show basic proof of exposure and injury early. That burden falls hardest on older farmers whose decades-old records may no longer exist.

What the science fight changed

The settlement fight cannot be understood without the causation fight behind it. The first bellwether cases — early test cases chosen to show how juries might respond to shared evidence — never reached a jury, because the court excluded the plaintiffs' general causation expert under Daubert, the standard for whether expert testimony is reliable enough for a jury to hear. The cases were dismissed in April 2024, and new experts would have to survive a renewed challenge.

Regulators have not settled the science either: on January 30, 2024, the Environmental Protection Agency concluded the evidence was insufficient to link registered pesticidal paraquat use to Parkinson's disease in humans — a regulatory finding, not a jury standard, but one defendants rely on heavily. And on June 25, 2026, the Supreme Court ruled in Monsanto v. Durnell that federal pesticide law can preempt state failure-to-warn claims, unsettling a central theory in these cases, as our earlier analysis of paraquat after Durnell explains. If the settlement collapses, returning cases will face a harder landscape than the ones filed years ago.

Who Benefits From This — and Who Does Not

Farmworkers and applicators who personally mixed, sprayed, or handled paraquat and later developed Parkinson's disease are the readers this story matters most to: the judge's orders decide whether their claims are paid through the settlement or tested, case by case, in court. If you have documented years of paraquat use and a Parkinson's diagnosis, the court's insistence on proof helps you. Our guide to who qualifies in MDL 3004 explains the exposure evidence courts look for first.

This story does not help everyone. People who never worked with paraquat, lived far from any application, and cannot identify a product or a period of exposure are unlikely to benefit from either path, since both demand the same basic proof. Nor anyone seeking a quick payout: terms are confidential and no payment schedule is public. For why so many plaintiffs rejected the deal, see our report on the 900-plus rejections and what the MDL does next.

Frequently Asked Questions

Who benefits from the paraquat settlement — and who is a holdout?

Plaintiffs who accept trade litigation's uncertainty for a payment under confidential terms. Holdouts keep their lawsuits but must prove exposure and diagnosis under demanding court orders.

Who does not benefit from this litigation?

People without documented paraquat exposure or a Parkinson's diagnosis do not benefit from either path, since both require that proof — nor anyone expecting a fast, fixed payment.

How do I benefit, or how do I start, if I was exposed to paraquat?

Gather proof first: applicator or employment records showing paraquat use, medical records confirming a Parkinson's diagnosis, and a timeline linking the two. Then have an attorney check your state's deadline and forum.

What happens if the settlement collapses entirely?

The judge is likely to revive bellwether test trials before juries — a path taking years, under the harder landscape created by the Daubert rulings and the 2026 preemption decision.

Can the judge force a plaintiff to accept the settlement?

No. She can only require plaintiffs who reject it to appear, produce records, sit for depositions, and certify in writing that their decision was informed.

This article is general information about court proceedings, not legal advice. Settlement outcomes, deadlines, and eligibility depend on individual facts and state law; speak to a qualified attorney about your own case.

Watch on YouTube

Problem Solved on YouTube